<!DOCTYPE html>
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="robots" content="noindex">
<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
<link href="css-reset.css" rel="stylesheet" type="text/css">
<link href="style.css" rel="stylesheet" type="text/css">
<link rel="shortcut icon" href="favicon.ico" type="image/x-icon">
<link rel="icon" href="favicon.ico" type="image/x-icon">
<title>IONSYS™ (fentanyl iontophoretic transdermal system)</title> 
</head>

<body>
<div class="phonegapBlack">
	<div>
		<div class="introLogo">
		</div>
		<p>
			IONSYS is indicated for the management of acute moderate to severe post-operative pain in adult patients.
			<br><br>
			IONSYS is restricted to hospital use only. Treatment should be initiated by and remain under the guidance of a physician experienced in the management of opioid therapy.
			<br><br>
			Tap to continue.
		</p>
	</div>
</div>
<div class="languageBar">
	<div class="languageList hiddenList">
		<ul>
			<a href="index_AT.html"><li class="language" id="langAT"><span>AT</span></li></a>
			<a href="index_DA.html"><li class="language "><span>DA</span></li></a>
			<a href="index_DE.html"><li class="language "><span>DE</span></li></a>
			<a href="index_FI.html"><li class="language "><span>FI</span></li></a>
			<a href="index_FR.html"><li class="language "><span>FR</span></li></a>
			<a href="index_NL.html"><li class="language "><span>NL</span></li></a>
			<a href="index_NO.html"><li class="language "><span>NO</span></li></a>
			<a href="index_SE.html"><li class="language "><span>SE</span></li></a>
		</ul>
	</div>	
	<div class="languageSelector"></div>
</div>

<div class="debugLog hidden">debug</div>

<header class="pageHeader frontHeader">
	<div id="headerLogoCircle hidden">
	</div>
</header>

<header class="pageHeader frontHeader powerButtonContainer">
	<button id="powerButton">
		<i class="flaticon-standby"></i>
	</button>
	<button id="powerButtonOff">
		<i class="flaticon-standby"></i>
	</button>
</header>	
<section class="splash">
	<div class="splashLimiter">
		<header class="ionsysLogo">
		</header>
		<div class="backgroundAssembly"></div>
		<div class="container packageAssembly">
			<div class="bottomAssy">
				<div class="bottomAssySnapPoint"></div>
			</div>
			<div class="topAssy" draggable="true">
			</div>
		</div>
		<div class="container workingAssembly hidden">
			<div class="device" id="ionsysSplash">
				<div class="led ledGreen hidden">
				</div>
				<div class="led ledRed hidden">
				</div>
				<div class="doseButton">
				</div>
				<div class="seven-segment">
					<div class="digit tens">
						  <div class="a"></div>
						  <div class="b"></div>
						  <div class="c"></div>
						  <div class="d"></div>
						  <div class="e"></div>
						  <div class="f"></div>
						  <div class="g"></div>
					</div>
					<div class="digit ones">
						  <div class="a"></div>
						  <div class="b"></div>
						  <div class="c"></div>
						  <div class="d"></div>
						  <div class="e"></div>
						  <div class="f"></div>
						  <div class="g"></div>
					</div>
				</div>
			</div>
			<div id="medcoLogo" class="hidden">
				<img src="img-medcologo-long-black-clr.png">
			</div>
		</div>
		<div class="container context invisible">
			<div class="contextOverflow">
				<div class="contextContent">
					<header>
						<h2 id="deviceStatus">
							<p class="statusDefault enable"></p>
							<p class="statusReady">Ready Mode</p>
							<p class="statusDose1">Dosing</p>
							<p class="statusDose2">Dosing</p>
							<p class="statusPsc1">Poor Skin Contact</p>
							<p class="statusPsc2">Poor Skin Contact</p>
							<p class="statusEou">End of Use</p>
							<p class="statusEol">System Error</p>
							<p class="statusPoweron">Powering On</p>
							<p class="statusPoweroff"><!-- Powering Off --></p>
							<p class="statusPoweredoff"><!-- Powered Off --></p>
							<p class="statusCustom">custom</p>
						</h2>
					</header>
					<article class="caption">
						<h4 id="modeCaption" class="hidden">
							<p class="statusDefault enable"></p>
							<p class="statusReady">Ready for Dose Initiation</p>
							<p class="statusDose1">Administering Dose...</p>
							<p class="statusDose2">Administering Dose...</p>
							<p class="statusPsc1">NO dose being delivered</p>
							<p class="statusPsc2">NO dose being delivered</p>
							<p class="statusEou">80 doses or 24 hours</p>
							<p class="statusEol">ALERT mode</p>
							<p class="statusPoweron"><!-- Powering On --></p>
							<p class="statusPoweroff"><!-- Powering Off --></p>
							<p class="statusPoweredoff"><!-- Powered Off --></p>
							<p class="statusCustom">custom</p>
						</h4>
						<div id="modeDescription">
							<p class="statusDefault enable"></p>
							<p class="statusReady">
								The device is powered and ready to administer a dose. A dose can be administered by pressing the dose button on the top of the device two times in a window of 3 seconds between button presses. No fentanyl is delivered in this mode until a dose is initiated.
								<span class="mockButton mbEOU">If the unit reaches the 24-hour limit or 80 doses, it will enter End-of-Use.</span>
								<span class="mockButton mbEOL">If the unit fails self-test or has low battery, it will sound an ALERT and enter System Error.</span>
							</p>
							<p class="statusDose1">
								Delivery of a dose of fentanyl. The dosing period is 10 minutes long and delivers 40 mcg of medicine to the patient. During this period, the dose button is disabled, the LED flashes green, and the display indicates that it is in a dosing mode due to the 'walking' LCD animation alternating with the current doses administered.
								<span class="mockButton mbPSC">If the unit senses poor skin contact, it will stop dosing, enter Standby mode, then return to Ready mode.</span>
								<span class="mockButton mbEOU">If the unit reaches the 24-hour limit or 80 doses, it will enter End-of-Use.</span>
								<span class="mockButton mbEOL">If the unit senses compromised skin (i.e. an open wound), it will sound an ALERT and enter System Error.<span>
							</p>
							<p class="statusPsc1">
								When a dose is initiated BUT the device does not detect proper contact with the patient's skin after 4 minutes, the unit will stop dosing, enter Standby mode and inform the patient. This is indicated by audible beeping along with a flashing red LED. 
								<span>The device will enter Standby mode for 15 seconds, the dose count will not increment, and the device can re-administer a dose after it returns to Ready mode after 15 seconds.</span>
							</p>
							<p class="statusEou">
								After 80 doses are administered or 24 hours pass since activation, the device will enter End-of-Use mode. The device will no longer administer any doses, the LCD will flash the total number of doses administered, and the LED does not flash.
								<span class="mockButton mbEOL">After 12 hours in End-of-Use, the device will enter System Error mode automatically.</span>
								<span>Holding down the dose button for 6 seconds will turn off the unit.</span>
							</p>
							<p class="statusEol">
								An ALERT condition can occur by sensing compromised skin mid-dose, from a low battery, or after 12 hours from End-of-Use. It will flash the current dose amount on the LCD, the LED will contintually blink red and an audible continuous beep will play. This indicates that the device has reached EOL (End of Life). No doses may be administered.
								<span>Holding down the dose button for 6 seconds will turn off the unit.</span>
							</p>
							<p class="statusPoweron"></p>
							<p class="statusPoweroff"></p>
							<p class="statusPoweredoff"></p>
							<p class="statusCustom">custom</p>
						</div>
					</article>
<!-- 					<footer>
						<h3 id="modeFooter" class="hidden">
							<p class="statusDefault enable"></p>
							<p class="statusReady">Standby, Ready.</p>
							<p class="statusDose1">Administering Dose...</p>
							<p class="statusPsc1">Poor Skin Contact, no dose being delivered...</p>
							<p class="statusEou">Currently in End of Use mode...</p>
							<p class="statusEol">Currently in End of Life mode.../p>
							<p class="statusPoweron">Powering On</p>
							<p class="statusPoweroff">Powering Off</p>
							<p class="statusPoweredoff">Powered Off</p>
							<p class="statusCustom">custom</p>
						</h3>
					</footer> -->
				</div>
			</div>
			<div class="contextArrowContainer">
				<div class="flaticon-arrow395 contextArrow contextArrowClosed"></div>
			</div>
		</div>
		<div class="control">
			<label for="doseNumber"  class="extraButtons hidden" >Set Dose #: </label>
			<input type="number" name="doseNumber" id="doseNumber"  class="extraButtons hidden" min="0" max="99" value="0" ></input>
		</div>
	</div>
</section>
<header class="ionsysLogoBanner hiddenLogo">
	<div class="mdcoLogo">
	</div>
</header>
<section class="infoPage">
	<div class="infoPageContent">
		<!-- <header class="ionsysLogo">
			<img src="logo-ionsys-text-2.png">
			<h3>information</h3>
		</header> -->
		<table class="infoPageTable">
			<td colspan="2">
				IONSYS is indicated for the management of acute moderate to severe post-operative pain in adult patients.
			</td>
		</table>
		<table class="infoPageTable">
			<td colspan="2">
			IONSYS is restricted to hospital use only. Treatment should be initiated by and remain under the guidance of a physician experienced in the management of opioid therapy.
			</td>
		</table>
		<table class="infoPageTable">
			<tr>
				<th colspan="2">
					<h3>SYSTEM SPECIFICATIONS</h3>
				</th>
			</tr>
			<tr>
				<td>
					Active Ingredient
				</td>
				<td>
					Fentanyl HCl
				</td>
			</tr>
			<tr>
				<td>
					Absorption route:
				</td>
				<td>
					Transdermal (iontophoresis)
				</td>
			</tr>
			<tr>
				<td>
					Activation:
				</td>
				<td>
					Patient double-clicks on-demand dosing button (twice within 3 seconds)
				</td>
			</tr>
			<tr>
				<td>
					Dosing:
				</td>
				<td>
					Pre-programmed 40 micrograms delivered over 10-minute dosing period*
				</td>
			</tr>
			<tr>
				<td>
					Maximum dose rate:
				</td>
				<td>
					6 doses per hour
				</td>
			</tr>
			<tr>
				<td>
					Lockout period*:
				</td>
				<td>
					<p>10 minutes (coincides with dosing period)</p>
				</td>
			</tr>
			<tr>
				<td>
					Doses available per unit:
				</td>
				<td>
					80
				</td>
			</tr>
			<tr>
				<td>
					Dispensing life:
				</td>
				<td>
					24 hours or 80 doses, whichever comes first
				</td>
			</tr>
			<tr>
				<td colspan="2">
					<p class="infoSidenote">
						*(10 minute period is shortened to 18 seconds in this app for demonstration purposes)
					</p>
				</td>
			</tr>
		</table>
				<table class="infoPageTable infoColumn" align="left">
					<tbody>
						<th>
							<h3>FEATURES</h3>
						</th>
						<tr>
							<td>
								<ul>
									<li>On-demand dosing button</li>
									<li>Light-emitting diode (LED) that indicates:
										<ul>
											<li>When a dose is being delivered (Green)</li>
											<li>When there is an error (Red)</li>
										</ul>
									</li>
								</ul>
							</td>
						</tr>
					</tbody>
				</table>
				<table class="infoPageTable infoColumn" align="left">
					<tbody>
						<tr>
							<td>
								<ul>
									<li>Liquid-crystal display (LCD) that indicates:
										<ul>
											<li>The number of doses delivered</li>
											<li>When a dose is being administered</li>
											<li>When there is an error</li>
										</ul>
									<li>Audio tones that signal dose activation and various system alerts</li>
									<li>Pressure-sensitive adhesive that holds IONSYS securely to patient's skin</li>

	<!-- 								<li>Designed system features:
										<ul>
											<li>IONSYS is pre-programmed to give a precise dose of pain medication</li>
											<li>IONSYS is pre-programmed to prevent the patient from getting more than one dose at a time. The patient is limited to a maximum of 6 doses per hour</li>
											<li>The recessed on-demand dosing button and the "double-click" needed to start a dose protect against accidentally starting a dose</li>
										</ul>
									</li>
									<li>IONSYS contains no latex</li> -->
								</ul>
							</td>
						</tr>
					</tbody>
				</table>
				<table class="infoPageTable smpc">
					<tr>
						<td>
							<h3>
								IONSYS 40 MICROGRAMS PER DOSE TRANSDERMAL SYSTEM (FENTANYL)
							</h3>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								ABBREVIATED PRESCRIBING INFORMATION 
							</h3>
							<h4>
								(refer to full Summary of Product Characteristics [SmPC] before prescribing).
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Presentations
							</h3>
							<h4>
								IONSYS is a transdermal system. Each IONSYS system contains fentanyl hydrochloride equivalent to 9.7 mg of fentanyl and delivers 40 micrograms fentanyl per dose, to a maximum of 80 doses (3.2 mg/24 hours).

							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Indication
							</h3>
							<h4>
								IONSYS is indicated for the management of acute moderate to severe post-operative pain in adult patients.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Posology and method of administration
							</h3>
							<h4>
								Refer to full SmPC for complete information on posology and administration. IONSYS is a patient-controlled device restricted to hospital use only. Treatment should be initiated by and remain under the guidance of a physician experienced in the management of opioid therapy. Due to the well-known potential of abuse of fentanyl, physicians should evaluate patients for a history of drug abuse.
							</h4>
							<h4>
								<i>Recommended dosage:</i> Each dose delivers 40 micrograms of fentanyl over a 10 minute period. Each unit operates for 24 hours or for 80 doses, whichever comes first, and then becomes inoperative. The maximum treatment duration is 72 hours.
							</h4>
								<i>Elderly (≥65 years): </i>No specific dose adjustment is required. Elderly patients should be observed closely for adverse effects of fentanyl.
							</h4>
							<h4>
								<i>Hepatic or renal impairment:</i> Administer with caution to patients with moderate or severe hepatic or renal impairment
							</h4>
							<h4>
								<i>Paediatric population:</i> Not recommended.
							</h4>
							<h4>
								<i>Method of administration:</i> For transdermal use only. Refer to full SmPC for complete information on method of administration and instructions for use and disposal of IONSYS.  
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Contraindications
							</h3>
							<h4>
								Hypersensitivity to active substance or any excipient.
							</h4>
							<h4>
								Severe respiratory depression or cystic fibrosis.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Special warnings and precautions for use
							</h3>
							<h4>
								IONSYS should be removed before MRI procedure, cardioversion, defibrillation, X-ray, CT scan or diathermy.
							</h4>
							<h4>
								Excessive sweating may reduce delivery of fentanyl.
							</h4>
							<h4>
								<i>Respiratory depression:</i> Significant respiratory depression may occur; patients must be observed for these effects. The use of concomitant CNS-active medicinal products may increase the risk of respiratory depression.
							</h4>
							<h4>
								<i>Chronic pulmonary disease:</i> Patients with chronic obstructive pulmonary disease or patients with conditions pre-disposing them to hypoventilation, may experience more severe adverse reactions. In such patients, opioids may decrease respiratory drive and increase airway resistance.
							</h4>
							<h4>
								<i>Head injuries and increased intracranial pressure:</i> Fentanyl should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention. Fentanyl should be used with caution in patients with brain tumours or other significant space occupying lesions of the brain.
							</h4>
							<h4>
								<i>Cardiac disease:</i> Fentanyl may produce bradycardia or hypotension and should be administered with caution to patients with bradyarrhythmias or any significant cardiovascular disease.
							</h4>
							<h4>
								<i>Paralytic ileus:</i> Should be used with caution in patients with paralytic ileus.
							</h4>
							<h4>
								<i>Abuse potential and dependence:</i> Fentanyl has a well-known abuse potential. Physicians should evaluate patients for a history of drug abuse and follow such patients closely. 
							</h4>
							<h4>
								<i>Hepatic or renal disease:</i> Patients with hepatic or renal impairment should be observed carefully for signs of fentanyl toxicity.
							</h4>
							<h4>
								<i>Elderly patients:</i> Elderly patients should be observed carefully for adverse effects of fentanyl during IONSYS administration.
							</h4>
							<h4>
								<i>Obese patients:</i> Overall adverse reaction profile for morbidly obese patients (BMI > 40) does not suggest a meaningful difference in safety compared to patients with BMI ≤ 40. Caution is advised when prescribing IONSYS in these patients as they may be at increased risk of other respiratory conditions (i.e., sleep apnoea) potentially pre-disposing them to hypoventilation or more severe adverse reactions.
							</h4>
							<h4>
								<i>Hearing impairment:</i> IONSYS should be used with caution in patients with hearing impairment who might not be able to hear the audible signals from the system. 
							</h4>
							<h4>
								<i>Thoracic/chest and upper abdominal surgeries:</i> IONSYS should be used with caution in these patients. 
							</h4>
							<h4>
								<i>Physical status:</i> Safety of IONSYS has not been established in patients with American Society of Anesthesiologists (ASA) physical status classification IV (i.e. patients with a severe systemic disease that is a constant threat to life).
							</h4>
							<h4>
								<i>Patients with genetic polymorphisms affecting CYP3A4 and CYP3A5:</i> IONSYS should be used with caution in these patients. Published literature indicates potential for increased fentanyl exposure in patients with genetic polymorphisms affecting CYP3A4 and CYP3A5; 
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Interaction with other medicinal products and other forms of interaction
							</h3>
							<h4>
								<i>Other CNS depressants:</i> Concomitant use with other CNS depressants may produce additive depressant effects. Hypoventilation, hypotension and profound sedation or coma may occur. Use of other CNS depressants concomitantly with IONSYS requires special patient care and observation.
							</h4>
							<h4>
								<i>CYP3A4 inhibitors: </i>Concomitant use of potent CYP3A4 inhibitors  or moderate CYP3A4 inhibitors  with IONSYS may result in an increase in fentanyl plasma concentrations, which could increase or prolong both the therapeutic effect and adverse reactions, and may cause serious respiratory depression. Concomitant use of potent or moderate CYP3A4 inhibitors and IONSYS is not recommended unless the patient is closely monitored.
							</h4>
							<h4>
								<i>Opioid agonists/antagonists:</i> Concomitant use of partial opioid agonists/antagonists is not recommended as they may induce withdrawal symptoms in opioid dependant patients.
							</h4>
							<h4>
								<i>Serotoninergic medicinal products:</i> Co-administration of fentanyl with a serotoninergic agent may increase the risk of serotonin syndrome. IONSYS is not recommended for use in patients who have received MAOIs within 14 days because severe and unpredictable potentiation by MAOIs has been reported. 
							</h4>
							<h4>
								<i>Topical medicines: </i>Application of IONSYS on skin on which any topical medicine has been applied should be avoided.  
							</h4>
							<h4>
								Refer to full SmPC for further information on interactions. 
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Fertility, pregnancy and lactation
							</h3>
							<h4>
								<i>Pregnancy:</i> No adequate data are available for use of fentanyl in pregnant women. IONSYS should not be used in pregnancy unless clearly necessary. If IONSYS is administered to the mother during this time, an antidote for the child should be readily available.  Following long-term treatment fentanyl may cause withdrawal symptoms in the newborn.
							</h4>
							<h4>
								<i>Breast-feeding:</i> Not recommended for 24 hours following removal of IONSYS. 
							</h4>
							<h4>
								<i>Fertility:</i> There are no clinical data on the effects of fentanyl on fertility. 
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Effects on ability to drive and use machines
							</h3>
							<h4>
								Patients should be advised not to drive or operate machinery if they experience somnolence, dizziness, or visual disturbance.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Undesirable effects 
							</h3>
							<h4>
								The  most commonly reported adverse reactions were nausea, vomiting, and application site reactions. The most serious adverse reactions reported were hypotension and apnoea; all patients should be closely monitored for these. Refer to full SmPC for complete information on other side effects.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Overdose
							</h3>
							<h4>
								Fentanyl overdose effects manifest as an extension of its pharmacologic actions, the most serious effect being respiratory depression. For management of respiratory depression, immediate countermeasures include removing the IONSYS system and physically or verbally stimulating the patient. These actions can be followed by administration of a specific opioid antagonist such as naloxone. Respiratory depression following an overdose may outlast the duration of action of the opioid antagonist therefore repeated administration of the antagonist may be necessary. Reversal of the narcotic effect may also result in acute onset of pain and release of catecholamines. If the clinical situation warrants, a patent airway should be established and maintained, possibly with an oropharyngeal airway or endotracheal tube. Oxygen should be administered and respiration assisted or controlled. If severe or persistent hypotension occurs, hypovolaemia should be considered and the condition should be managed with appropriate parenteral fluid therapy or other interventions. 
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Legal Category
							</h3>
							<h4>
								Prescription only
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Package Quantities & Costs 
							</h3>
							<h4>
								600 GBP for one box containing 6 IONSYS units
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Marketing Authorisation Holder
							</h3>
							<h4>
								Incline Therapeutics Europe Ltd, 21 St. Thomas Street, Bristol BS1 6JS, United Kingdom.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Marketing Authorisation Number
							</h3>
							<h4>
								EU/1/15/1050/001
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Date of last revision of the API text
							</h3>
							<h4>
								November 2015
							</h4>
							<h4>
								Any suspected adverse reactions should be reported. Reporting forms and information can be found at  www.mhra.gov.uk/yellowcard   
							</h4>
							<h4>
								or +44 (0)203 684 6344, Email: medical.information@themedco.com
							</h4>
						</td>
					</tr>
				</table>
			</tr>
			</tbody>
	</div>
</section>
<footer class="ionsysLogoBanner logoBannerBottom">
	<div class="ionsysLogo">
	</div>
</footer>
<div class="controlBar">
	<div class="controlButtonsContainer">
		<button id="poorSkin" class="extraButtons" disabled>PSC</button>
		<button id="EOU" class="extraButtons" disabled>
			<span>80/24</span>
		</button>		
		<button id="EOL" class="extraButtons" disabled></button>
		<button id="infoToggle" class="extraButtons">
		</button>	
	</div>
</div>
<audio id="beeper" preload="auto" src="beep.mp3"></audio>
<audio id="beeper-long" preload="auto" src="beep_long.mp3">	</audio>
<audio id="button-press" preload="auto" src="buttonpress.mp3"></audio>

</body>
<script src="http://ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>
<!-- make this a conditional if they are using phonegap and the online / cached copy is not available: -->
<script>window.jQuery || document.write('<script src="jquery-1.10.2.min.js">\x3C/script>')</script>
<script src="jquery-1.11.4-ui.min.js" type="text/javascript"></script>
<script src="jquery.ui.touch-punch.min.js" type="text/javascript"></script>
<script src="jquery.tap.js" type="text/javascript"></script>
<script src="phonegap.js"></script>
<script type="text/javascript" src="script.js"></script>
</html>